No Data
No Data
No Data
Insiders Are the Top Stockholders in Mabwell (Shanghai) Bioscience Co., Ltd. (SHSE:688062), and the Recent 12% Drop Might Have Disappointed Them
New stock news | Maiwei Bio has submitted its application to the Hong Kong Stock Exchange, with CITIC and Haitong as co-sponsors.
Maiwei Biotech is a pharmaceutical company primarily focused on the independent development of drugs for tumors and age-related diseases, currently in the commercialization stage.
Maiwei Biotech's targeted Nectin-4 ADC combined with PD-1 monoclonal antibody has received CDE approval to conduct phase III clinical research for the first-line treatment of urothelial carcinoma.
Shanghai, August 26, 2024 /PR Newswire/ -- Maiwei Biotech (688062.SH), an innovative biopharmaceutical company with a comprehensive Industry Chain layout, announced that its "randomized, controlled, open-label, multicenter Phase III clinical study protocol assessing the combination of 9MW2821 and Toripalimab compared to standard chemotherapy as first-line treatment for locally advanced or metastatic urothelial carcinoma patients" submitted to the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has been approved, and the combination of 9MW2821 and PD-1 monoclonal antibody for first-line treatment of urothelial carcinoma has been initiated.